Apr 23, 2024
https://visiblealpha.com/wp-content/uploads/2024/04/Meta-Microsoft-and-Alphabet_-April-2024-Earnings-Previews.jpg
628
1200
Melissa Otto, CFA
/wp-content/uploads/2019/09/visible-alpha-logo1.png
Melissa Otto, CFA2024-04-23 09:32:112024-04-23 09:32:11Meta, Microsoft, and Alphabet: April 2024 Earnings PreviewsApr 22, 2024
https://visiblealpha.com/wp-content/uploads/2024/04/The-Visible-Alpha-AI-Monitor_-Push-Towards-Enterprise-Adoption.jpg
628
1200
Melissa Otto, CFA
/wp-content/uploads/2019/09/visible-alpha-logo1.png
Melissa Otto, CFA2024-04-22 10:12:072024-04-22 10:21:41The Visible Alpha AI Monitor: A Push Towards Enterprise AdoptionApr 17, 2024
https://visiblealpha.com/wp-content/uploads/2024/04/Eli-Lillys-Donanemab-Treatment-for-Alzheimers-Faces-Regulatory-Approval-Delays.jpg
628
1200
Rahul Jasuja, PhD
/wp-content/uploads/2019/09/visible-alpha-logo1.png
Rahul Jasuja, PhD2024-04-17 12:06:422024-04-17 12:06:42Eli Lilly’s Donanemab Treatment for Alzheimer’s Disease Faces Regulatory Approval DelaysApr 15, 2024
https://visiblealpha.com/wp-content/uploads/2024/04/Indias-Telecom-Landscape-Jios-Rise-Airtels-ARPU-Surge-and-Vis-Downtrend.jpg
628
1200
Sweta Patra
/wp-content/uploads/2019/09/visible-alpha-logo1.png
Sweta Patra2024-04-15 11:45:442024-04-15 11:59:29India’s Telecom Landscape: Jio’s Rise, Airtel’s ARPU Surge, and Vi’s DowntrendApr 10, 2024
https://visiblealpha.com/wp-content/uploads/2024/04/Will-Google-Cloud-Achieve-a-Double-Digit-Profit-Margin-in-2025.jpg
628
1200
Melissa Otto, CFA
/wp-content/uploads/2019/09/visible-alpha-logo1.png
Melissa Otto, CFA2024-04-10 11:00:432024-04-10 11:10:11Will Google Cloud Achieve a Double-Digit Profit Margin in 2025?Mar 19, 2024
https://visiblealpha.com/wp-content/uploads/2024/03/Takeda-Pharmaceuticals-Qdenga-Dengue-Vaccine-Poised-for-Strong-Growth.jpg
628
1200
Ashutosh Raj
/wp-content/uploads/2019/09/visible-alpha-logo1.png
Ashutosh Raj2024-03-19 15:27:562024-03-19 15:27:56Takeda Pharmaceutical’s Qdenga Dengue Vaccine Poised for Strong GrowthMar 07, 2024
https://visiblealpha.com/wp-content/uploads/2024/03/Vertex-Pharmaceuticals-VX-548_-Potential-Blockbuster-Pain-Treatment.jpg
628
1200
Raunaq Sahil
/wp-content/uploads/2019/09/visible-alpha-logo1.png
Raunaq Sahil2024-03-07 11:52:192024-03-07 11:52:19Vertex Pharmaceuticals’ VX-548: Potential Blockbuster Pain TreatmentGet it Delivered
Get articles like these including investment research news and insights uncovered using the Visible Alpha platform delivered to your inbox.
Call Us
General Inquiries: +1 646 374 4702
Sales
Americas: +1 646 989-2621
Europe: +44 20 35451032
APAC: +852 3002 0647
Client Support
Americas: +1 646 462 3210
Europe: +44 20 3884 2798
APAC: +852 3002 0649